evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

9 questions · 9 findings · 4 reviews · Hepato-Biliary

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 11.1%GRADE not reported 0 · 0%Very low 8 · 88.9%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care

Adverse events considered non‐serious · participants with advanced hepatocellular carcinoma

It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes adverse events considered non‐serious (number of participants) compared with best supportive care alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).

1 finding from 1 review

Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care

Proportion of people with ≥ 1 serious adverse events (at 20 months) · participants with advanced hepatocellular carcinoma

It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with ≥ 1 serious adverse events (at 20 months) compared with best supportive care alone (very low certainty).

1 finding from 1 review

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).

1 finding from 1 review

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: total bilirubin elevation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).

1 finding from 1 review

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: serum transaminases elevation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).

1 finding from 1 review